Androinz.reverse_treatment.1.var Page

Key findings regarding androgen-targeted therapy resistance:

These truncated variants (like ARv567es) lack the ligand-binding domain but remain constitutively active, driving resistance to castration and newer antiandrogens. Androinz.Reverse_Treatment.1.var

While potent AR inhibitors are used, they can force tumors to de-differentiate into AR-negative disease. For more specific information, pleaseg., ARv567es or AR-V7) The effect of specific drugs (e.g., enzalutamide) The role of ROR-γ in treatment resistance To narrow this down, Clinical trial outcomes for resistance? A summary of new therapeutic targets being researched? A summary of new therapeutic targets being researched

Resistance is also mediated by non-canonical pathways, such as ROR-γ (retinoic acid receptor-related orphan receptor γ), which acts as a driver of AR expression in CRPC. For medical advice or diagnosis, consult a professional

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more

Antiandrogen treatment can cause stromal cell reprogramming, leading to SPP1+ myCAFs (myofibroblastic cancer-associated fibroblasts) that create a microenvironment resistant to androgen deprivation therapy.

Based on recent research into prostate cancer treatment, remains a key target, but therapy resistance (specifically, castration-resistant prostate cancer, or CRPC) is a major challenge. Research highlights that, while standard treatments like enzalutamide or abiraterone are used, tumor resistance often emerges through the adaptation of AR variants (e.g., AR-V7 , ARv567es ).